Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Journal Articles

Tissue Molecular Genotyping Improves Patient Blood Management in Syrian Injured Patients Treated in Israel

Luiza Akria, MD, Masad Barhoum, Simona Zisman-Rozen, Celia Suriu, Andrei Braester, MD, Ety Shaoul

Blood (2018) 132 (Supplement 1): 5076.

https://doi.org/10.1182/blood-2018-99-114061

Published: 2018

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Tanya Mashiach, MSc, Elinor Barzilai, BSc, Abraham Korenberg, MD, Luiza Akria, MD, Tamar Tadmor, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Olga Kagna, MD, Rosa Ruchlemer, MD, Neta Goldschmidt, MD, Netanel A. Horowitz, MD, David Lavie, MD, Dina Ben-Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2016) 128 (22): 3001.

https://doi.org/10.1182/blood.V128.22.3001.3001

Published: 2016

Journal Articles

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Tsila Zuckerman, MD, Stela Gengrinovitch, PhD, Ruth Ben-Yakar, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Maya Koren-Michowitz, MD, Shay Yeganeh, MD, Martin S. Tallman, MD, Jacob M. Rowe, MD

Blood (2016) 128 (22): 1650.

https://doi.org/10.1182/blood.V128.22.1650.1650

Published: 2016

Journal Articles

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

David Azoulay, PhD, Yair Herishanu, MD, Mika Shapiro, PhD, Yarden Brenshaft, Celia Suriu, MD, Luiza Akria, MD, Andrei Braester, MD

Blood (2016) 128 (22): 5562.

https://doi.org/10.1182/blood.V128.22.5562.5562

Published: 2016

Journal Articles

Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients

Tsila Zuckerman, MD, Ruth Ben Yakar, PhD, Stela Gengrinovitch, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Olga Nudelman, MD, Nuhad Haddad, MD, Martin S Tallman, MD, Jacob M. Rowe, MD

Blood (2015) 126 (23): 3810.

https://doi.org/10.1182/blood.V126.23.3810.3810

Published: 2015

Journal Articles

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Eldad J Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Elinor Sabbag, BSc., Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Rosa Ruchlemer, MD, Roxolyana Abdah-Bortnyak, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Netanel Horowitz, David Lavie, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2014) 124 (21): 4409.

https://doi.org/10.1182/blood.V124.21.4409.4409

Published: 2014

Journal Articles

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

David Azoulay, PhD, Celia Suriu, MD, Luiza Akria, MD, Netanel A Horowitz, MD, Andrei Braester, MD

Blood (2014) 124 (21): 2252.

https://doi.org/10.1182/blood.V124.21.2252.2252

Published: 2014

Journal Articles

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Drorit Merkel, MD, Kalman Filanovsky, MD, Ariel Aviv, MD, Moshe E. Gatt, MD, Yair Herishanu, MD, Ariela Arad, MD, Tamar Tadmor, MD, Najib Dally, MD, Aharon Ronson, MD, Luiza Akria, MD, Andrei Braester, MD, Arnon Nagler, MD, Ronit Leiba, MSc., Yishai Ofran, MD

Blood (2011) 118 (21): 3811.

https://doi.org/10.1182/blood.V118.21.3811.3811

Published: 2011

Journal Articles

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Liana Abdach, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Jacob M. Rowe, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MSc, FRCPC

Blood (2010) 116 (21): 2809.

https://doi.org/10.1182/blood.V116.21.2809.2809

Published: 2010

Journal Articles

Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival.

Tsila Zuckerman, MD, Tamar Katz, PhD, Nuhad Haddad, MD, Riva Fineman, MD, Irit Avivi, MD, Eldad J. Dann, MD, Dvora Sahar, PhD, Ana Oliven, MSc, Ety Hertz, Yishay Ofran, MD, Luiza Akria, MD, Michal Markovitz, Tal Faibish, MSc, Jacob M. Rowe, MD

Blood (2006) 108 (11): 318.

https://doi.org/10.1182/blood.V108.11.318.318

Published: 2006

NARROW

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Tissue Molecular Genotyping Improves Patient Blood Management in Syrian Injured Patients Treated in Israel

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only